6
↑6
↓0
—0
Evidence suggests Creatine mayincreaseEnergy metabolism.
5 studies (6 claims)
Emerging evidence
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| creatine kinase inhibitor (CKi) | Increases - increase in | glutathione metabolism and ferroptosis protection genes | HumanMolecular | — | Not specified | A covalent creatine kinase inhibitor ablates glioblastoma migration and sensitizes tumors to oxidative stress.cited 1× |
| lactoferrin and creatine combination | Increases - exert a more significant effect | energy metabolism | Animal | C57BL/6 mice with D-galactose-induced sarcopenia | Not specified in the abstract. | The Combination of Lactoferrin and Creatine Ameliorates Muscle Decay in a Sarcopenia Murine Model.cited 2× |
| Creatine supplementation | Increases - improves | brain energy metabolism | Human | — | Not specified | Creatine Supplementation in Depression: A Review of Mechanisms, Efficacy, Clinical Outcomes, and Future Directions.cited 1× |
| creatine supplementation | Increases - may lead to improvements | muscle metabolism | Human | children with JDM | Not specified in the abstract. | The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis: A Randomized, Double-blind, Placebo-controlled Feasibility Study.cited 10× |
| creatine | Increases - statistically significant adaptations | muscle metabolism | Human | patients with juvenile dermatomyositis (JDM) | Not specified in the abstract. | The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis: A Randomized, Double-blind, Placebo-controlled Feasibility Study.cited 10× |
| creatine transporter mutation (Slc6a8-/y) | No effect - demonstrate marked differences in | glucose metabolism in the brains | Animal | wild type and Slc6a8-/y mice | Not specified | [18F]FDG-PET and [18F]MPPF-PET are brain biomarkers for the creatine transporter Slc6a8 loss of function mutation. |
| new approaches in treating mutations of the creatine transporter SLC6A8 | Increases - effectiveness in normalizing | brain metabolism | Animal | — | Not specified | [18F]FDG-PET and [18F]MPPF-PET are brain biomarkers for the creatine transporter Slc6a8 loss of function mutation. |